How Vast Government Aid and Imaginative Enforcement Could Mean FCA Liability for a Growing Breadth of Industries
Client Alert | less than 1 min read | 06.10.21
Over the past few years, both the government and False Claims Act relators (whistleblowers) have targeted more types of defendants than they have ever previously. Against this backdrop, Congress passed two of the largest relief bills in modern history and thus even more companies find themselves involved with the federal government in a new way or for the first time This article examines the government’s enforcement of FCA against such new or non-traditional defendants and provides key takeaways.
Contacts
Insights
Client Alert | 5 min read | 04.13.26
EU Pharma Package: Global (Orphan) Marketing Authorization Compromise Proposal
In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA), We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product.
Client Alert | 4 min read | 04.10.26
CMS Finalizes Rate Notice for Medicare Parts C and D (CY 2027)
Client Alert | 2 min read | 04.10.26
Client Alert | 4 min read | 04.10.26
FTC Issues Five-Year Strategic Plan: What Businesses Need to Know

